Skip to Main content Skip to Navigation
Journal articles

HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway

Abstract : Gastric cancer (GC) remains a health issue due to the low efficiency of therapies, such as cisplatin. This unsatisfactory situation highlights the necessity of finding factors impacting GC sensibility to therapies. We analyzed the cisplatin pangenomic response in cancer cells and found HDAC4 as a major epigenetic regulator being inhibited. HDAC4 mRNA repression was partly mediated by the cisplatin-induced expression of miR-140. At a functional level, HDAC4 inhibition favored cisplatin cytotoxicity and reduced tumor growth. Inversely, overexpression of HDAC4 inhibits cisplatin cytotoxicity. Importantly, HDAC4 expression was found to be elevated in gastric tumors compared to healthy tissues, and in particular in specific molecular subgroups. Furthermore, mutations in HDAC4 correlate with good prognosis. Pathway analysis of genes whose expression in patients correlated strongly with HDAC4 highlighted DNA damage, p53 stabilization, and apoptosis as processes downregulated by HDAC4. This was further confirmed by silencing of HDAC4, which favored cisplatin-induced apoptosis characterized by cleavage of caspase 3 and induction of proapoptotic genes, such as BIK, in part via a p53-dependent mechanism. Altogether, these results reveal HDAC4 as a resistance factor for cisplatin in GC cells that impacts on patients' survival.
Complete list of metadata

Cited literature [58 references]  Display  Hide  Download
Contributor : Christian Gaiddon Connect in order to contact the contributor
Submitted on : Thursday, November 14, 2019 - 12:04:18 PM
Last modification on : Wednesday, December 1, 2021 - 2:36:21 PM
Long-term archiving on: : Saturday, February 15, 2020 - 2:22:15 PM


Publisher files allowed on an open archive




Marie-Elodie Spaety, Alexandre Gries, Amandine Badie, Aina Venkatasamy, Benoît Romain, et al.. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers, MDPI, 2019, 11 (11), pp.1747. ⟨10.3390/cancers11111747⟩. ⟨inserm-02363213⟩



Record views


Files downloads